PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsInsulin, isophane
Insulin isophane
Insulin, isophane is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Humulin, Novolin
Combinations
Humulin, Novolin
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin isophane human
Tradename
Proper name
Company
Number
Date
Products
Humulin Ninsulin isophane humanEli LillyN-18781 OTC1982-10-28
3 products
Novolin Ninsulin isophane humanNovo NordiskN-19959 OTC1991-07-01
2 products
Insulin human
+
Insulin isophane human
Tradename
Proper name
Company
Number
Date
Products
Humulin 70/30insulin isophane human and insulin humanEli LillyN-19717 OTC1989-04-25
3 products
Novolin 70/30insulin isophane human and insulin humanNovo NordiskN-19991 OTC1991-06-25
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
fiaspBiologic Licensing Application2023-06-21
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
2307 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E131321142041734301016
Type 1 diabetes mellitusD003922EFO_0001359E1012712212486377801
Type 2 diabetes mellitusD003924EFO_0001360E116255197236238773
Insulin resistanceD007333EFO_0002614E88.8193132224274194
HyperglycemiaD006943—R73.988153052109
HypoglycemiaD007003—E16.271761061100
ObesityD009765EFO_0001073E66.9135962859
Healthy volunteers/patients———413—1651
Gestational diabetesD016640—O24.4—5751531
Metabolic syndromeD024821EFO_0000195E88.81037321528
Show 101 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SyndromeD013577——223—1116
Breast neoplasmsD001943EFO_0003869C50351—613
Covid-19D000086382—U07.1112—59
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9—24—39
Cystic fibrosisD003550EFO_0000390E84—34—37
Myocardial ischemiaD017202EFO_1001375I20-I252—2—37
Cognitive dysfunctionD060825—G31.84—21—57
AsthmaD001249EFO_0000270J45—15——6
Cardiac surgical proceduresD006348————1—45
Autoimmune diseasesD001327EFO_0000540M30-M36—21—25
Show 56 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HyperinsulinismD006946—E16.161——411
NeoplasmsD009369—C8061——29
PainD010146EFO_0003843R52—1——78
Heart failureD006333EFO_0003144I5033——37
Premature birthD047928EFO_0003917O60—3——36
Alzheimer diseaseD000544EFO_0000249F03—1——56
PregnancyD011247EFO_0002950Z33.1—1——34
Rare diseasesD035583———1——34
UlcerD014456MPATH_579——1——23
Major depressive disorderD003865EFO_0003761F2212——13
Show 85 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart diseasesD006331EFO_0003777I51.91———56
Carpal tunnel syndromeD002349EFO_0004143G56.01———34
Intracranial aneurysmD002532EFO_0003870I67.11———23
FastingD005215EFO_0002756—1———23
Insulin infusion systemsD007332——1———23
MelanosisD008548EFO_0003963L81.12———13
Brain neoplasmsD001932EFO_0003833C712————2
GliomaD005910EFO_0000520—2————2
TendinopathyD052256EFO_1001434M77.91———12
Aortic aneurysmD001014EFO_0001666I71.91———12
Show 28 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—————66
Surgical wound infectionD013530——————66
Injection site reactionD000075662——————55
ExerciseD015444EFO_0000483—————55
Critical careD003422——————55
Diabetes complicationsD048909——————44
Communicable diseasesD003141——————44
EmergenciesD004630——————33
Therapeutic equivalencyD013810——————33
InfertilityD007246EFO_0000545—————33
Show 171 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameInsulin isophane
INN—
Description
Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, is an intermediate-acting insulin given to help control blood sugar levels in people with diabetes. It is used by injection under the skin once to twice a day. Onset of effects is typically in 90 minutes and they last for 24 hours. Versions are available that come premixed with a short-acting insulin, such as regular insulin.
Classification
Protein
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108964
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID—
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Fiasp – Novo Nordisk
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Humulin – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 12,367 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,465 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use